Incyte (INCY) Revenue Growth (1y) (2011 - 2026)
Incyte (INCY) Revenue Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,831.58 Bn | 66,831.30 Bn | - | - |
| 2 | Nanobiotix | 1,916.61 Bn | 1,916.55 Bn | - | - |
| 3 | Akari Therapeutics | 976.78 Bn | 976.78 Bn | - | - |
| 4 | BeOne Medicines | 471.48 Bn | 466.69 Bn | 1.35 Bn | 35.46% |
| 5 | Vertex Pharmaceuticals | 121.78 Bn | 114.53 Bn | 2.59 Bn | 7.82% |
| 6 | Regeneron Pharmaceuticals | 69.87 Bn | 61.12 Bn | 3.31 Bn | 19.04% |
| 7 | Belite Bio | 63.06 Bn | 63.06 Bn | - | - |
| 8 | Argenx Se | 55.78 Bn | 50.60 Bn | 1.41 Bn | 64.03% |
| 9 | Alnylam Pharmaceuticals | 37.54 Bn | 34.53 Bn | 959.66 Mn | 96.43% |
| 10 | Incyte | 23.75 Bn | 19.73 Bn | 1.17 Bn | 20.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 20.87% |
| Dec 31, 2025 | 27.84% |
| Sep 30, 2025 | 20.05% |
| Jun 30, 2025 | 16.46% |
| Mar 31, 2025 | 19.53% |
| Dec 31, 2024 | 16.32% |
| Sep 30, 2024 | 23.81% |
| Jun 30, 2024 | 9.34% |
| Mar 31, 2024 | 8.93% |
| Dec 31, 2023 | 9.35% |
| Sep 30, 2023 | 11.63% |
| Jun 30, 2023 | 4.74% |
| Mar 31, 2023 | 10.29% |
| Dec 31, 2022 | 7.40% |
| Sep 30, 2022 | 1.27% |
| Jun 30, 2022 | 29.15% |
| Mar 31, 2022 | 21.25% |
| Dec 31, 2021 | 9.29% |
| Sep 30, 2021 | 30.99% |
| Jun 30, 2021 | 2.57% |